Table 1.
Patient and transplant characteristics.
| Number (%) | |
|---|---|
| Patients | 32 |
| Median age, years (range) | 41 (21–66) |
| Male | 17 (53%) |
| DISEASE | |
| Hodgkin lymphoma | 17 (53%) |
| Non-Hodgkin lymphoma | 11 (34%) |
| Acute lymphoblastic leukemia | 2 (6%) |
| Chronic lymphocytic leukemia | 1 (3%) |
| Acute myeloid leukemia | 1 (3%) |
| Myeloablative conditioning | |
| TBF | 3/32 (9%) |
| Reduced intensity conditioning (RIC)/non-myeloablative conditioning | |
| Baltimore | 22/32 (69%) |
| ONC005 | 6/32 (19)% |
| TBF RIC | 1/32 (3)% |
| Stem cell source | |
| Bone marrow | 31/32 (97%) |
| Peripheral blood stem cells | 1/32 (3%) |
| GvHD prophylaxis | |
| Pt-Cy + tacrolimus + MMF | 22/32 (69%) |
| Pt-Cy + CyA+ MMF | 10/32 (31%) |
| aGvHD grades II–IV | 7 (21.88%) |
| Median day of onset (range) | 41 (33–90) |
| aGvHD grades III–IV | 1 (17%) |
TBF, thiotepa (5 mg/kg; days -6, -5) - fludarabine (50 mg/m2; days -4, -3, -2) - busulfan (30 mg/kg; days -4, -3, -2); Baltimore = fludarabine (30 mg/m2; days -6, -5, -4, -3, -2) – cyclophosphamide (14.5 mg/kg; days -6, -5), total body irradiation (200 cGy), ONC005 = thiotepa (5 mg/kg twice a day; day -6) - fludarabine (30 mg/m2; days -5; -4, -3, -2) - cyclophosphamide (30 mg/kg; days -5); TBF RIC = thiotepa (5 mg/kg; days -6, -5) - fludarabine (50 mg/m2; days -4, -3, -2) - busulfan (3.2 mg/kg; days -4, -3); PT-Cy = post-transplant cyclophosphamide; MMF= mycophenolic acid; CyA = cyclosporin A.